Inicio>>Signaling Pathways>> Tyrosine Kinase>> Trk>>LM 22A4

LM 22A4

Catalog No.GC17835

LM 22A4 es un agonista específico del receptor B de tirosina quinasa, utilizado para la investigación de enfermedades neurológicas.

Products are for research use only. Not for human use. We do not sell to patients.

LM 22A4 Chemical Structure

Cas No.: 37988-18-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
67,00 $
Disponible
5mg
61,00 $
Disponible
10mg
108,00 $
Disponible
25mg
219,00 $
Disponible
50mg
383,00 $
Disponible
100mg
571,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.

LM22A-4 significantly up-regulates OPN and ALPase mRNA expression in a dose-dependent manner and OC mRNA level is significantly increased by 5 μM of LM22A-4. LM22A-4 significantly increases OPN, ALPase and OC mRNA expression in a time-dependent manner. LM22A-4 stimulated OPN and OC mRNA expression in HCEM cells cultured with mineralizing media[2].

LM22A-4 (10 mg/kg, i.p.) significantly reduces the degree of tissue injury and apoptosis (TUNEL staining and caspase-3 and Bcl-2 expression) compared with vehicle treated group. LM22A-4 also significantly ameliorates the recovery of limb function. LM22A-4 (10 mg/kg) treatment results in a significant increase in neuron number. LM22A-4 administration (10 mg/kg) significantly improves the neurological scores compared with those of the solvent-treated animals[1].

References:
[1]. Yu G, et al. Protective effects of LM22A-4 on injured spinal cord nerves. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. eCollection 2015.
[2]. Kajiya M, et al. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade. Int Immunopharmacol. 2014 Apr;19(2):245-52.

Reseñas

Review for LM 22A4

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LM 22A4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.